Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma

Clinical Trial ID NCT01185366

Rank	Title	Journal	Year	PubWeight™‹?›
1	A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma.	Eur Urol	2012	2.77
2	Management of renal collecting duct carcinoma: a systematic review and the McMaster experience.	Curr Oncol	2013	1.23
3	Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.	Eur Urol	2015	1.12
4	Targeted therapeutic strategies for the management of renal cell carcinoma.	Curr Opin Oncol	2012	1.00
5	Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies.	Front Oncol	2015	0.83
6	Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?	Oncologist	2012	0.78
7	First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium.	Clin Genitourin Cancer	2014	0.76
8	Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma.	Target Oncol	2011	0.75
9	Therapeutic challenges in advanced renal cell carcinoma.	Clin Pract (Lond)	2013	0.75